{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:01:12Z","timestamp":1775628072912,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.phrs.2021.105530","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T23:18:59Z","timestamp":1614986339000},"page":"105530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-3041","authenticated-orcid":false,"given":"Stefano","family":"Ciardullo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.phrs.2021.105530_bib1","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105530_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105530_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105530_bib4","doi-asserted-by":"crossref","unstructured":"KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease 2020. Kidney Int 98 (4s):S1-s115. doi:10.1016\/j.kint.2020.06.019.","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"10.1016\/j.phrs.2021.105530_bib5","unstructured":"Centers for disease control and prevention. 2017: National Health and Nutrition Examination Survey (NHANES). U.S. Department of health and human services. Available from https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?BeginYear=2017. 2017. (Accessed 10 April 2020)."},{"key":"10.1016\/j.phrs.2021.105530_bib7","unstructured":"Centers for disease control and prevention. 2017: National Health and Nutrition Examination Survey (NHANES). U.S. Department of health and human services. Available from https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/2017\u20132018\/manuals\/2017_MEC_Laboratory_Procedures_Manual.pdf (Accessed 31 March 2020)."},{"issue":"9","key":"10.1016\/j.phrs.2021.105530_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"15","key":"10.1016\/j.phrs.2021.105530_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"10166","key":"10.1016\/j.phrs.2021.105530_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.phrs.2021.105530_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2021.105530_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105530_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105052","article-title":"Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of sglt2-inhibitors and glp1-receptor agonists","volume":"160","author":"Berra","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"Supplement 1","key":"10.1016\/j.phrs.2021.105530_bib14","first-page":"S111","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.phrs.2021.105530_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/dom.13612","article-title":"How representative are the patients included in the cv outcome trials with sglt2 inhibitors of a general type 2 diabetes population? A large european observational study","volume":"21","author":"Birkeland","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2021.105530_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:22:35Z","timestamp":1760912555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":15,"alternative-id":["S1043661821001146"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105530","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105530"}}